On tissue NGS of immunotherapy-treated, SWI/SNF-altered pancreatic cancer patients, 7 patients harbored an ARID1A alteration (77%); 2 harbored an ARID1B mutation (22%); 3 harbored a SMARCA4 mutation (33%); 1 harbored a SMARCB1 mutation (11%); and 1 harbored a PBRM1 mutation (11%). Here, PBRM1 is linked to familial pancreatic carcinoma.